Travelling with lung disease
Travel is an essential part of everyday life in the twenty-first century, but may present challenges for those with chronic lung disease. What are the issues to be considered?
Travel, whether by car, coach, train or air, disrupts normal routine and relocates travellers to potentially unfamiliar surroundings. Medication may be forgotten or omitted because it was not packed or made readily available, because necessary equipment was too heavy to carry, or because of a lack of facilities, such as a glass of water for swallowing tablets or an electric socket to use a nebulizer.
Hypoxaemia is a concern when flying and/or travelling to high altitude destinations. Commercial aircraft are pressurized to cabin altitudes up to 2438 m (8000ft), when the partial pressure of oxygen equates to breathing 15.1% oxygen at sea level. In a healthy passenger PaO2 will fall to 7.0-8.5 kPa (SpO2 85-91%).' Altitude exposure may worsen hypoxaemia; particular caution seems appropriate in those hypoxaemic at sea level. In travellers staying at high altitude destinations the effect of hypoxaemia may be enhanced. Furthermore, central apnoeas during sleep, almost universal in healthy climbers above 2800m, may theoretically exacerbate obstructive sleep apnoea syndrome (OSAS).
There appears to be an association between long distance travel and venous thromboembolism (VTE); most data relate to air travel. Thrombosis risk rises after journeys exceeding eight hours; those at greatest risk have a history of VTE or risk factors. The risk of symptomatic VTE after flights over 12 hours is estimated at 0.5%.2 Stasis probably plays a major role; that of hypobaric hypoxia-induced coagulation activation is uncertain. Since immobility is common to all forms of travel, general preventative advice seems appropriate.
Infection is another consideration. The risks are best documented in relation to air travel, but increased risk of infection from overcrowding is equally likely in a train or coach. The greatest concern relates to pulmonary tuberculosis (TB), but the risks of exposure to respiratory viruses in passengers with lung disease are unknown, and there is uncertainty about the effects of air travel after recent respiratory tract infection. Finally, there are increasing concerns about worldwide transmission of hitherto uncharacterized infections, such as severe acute respiratory syndrome (SARS).
Dehydration may result from reduced fluid intake and low environmental humidity on long haul flights. This could theoretically trigger bronchospasm and secretion retention with possible lobar or segmental collapse; there are no data quantifying the risk.
What recommendations should be given to those with lung disease who wish to travel? Medication, including reliever and preventer inhalers, should always be carried readily available in hand luggage; bottled water may help in taking tablets. Spacers are as effective as nebulizers for relieving bronchospasm; consideration should be given to offering patients a spacer, with instructions on its use, for travelling. A written summary of medication may improve compliance; adjustments may be required if crossing several time-zones. If contemplating taking additional equipment patients should consult the tour operator or airline beforehand. Arranging medical insurance is vital.
Patients with severe lung disease, especially with hypoxaemia, a recent hospital admission for respiratory illness including pneumothorax, or a history of problems when flying, should be assessed before air travel. Some may require hypoxic challenge testing.' General advice to reduce the risk of VTE includes remaining as mobile as possible and avoiding excessive alcohol and caffeine; more specific recommendations for high risk travellers include graduating compression stockings, pre-flight aspirin, low molecular weight heparin or formal anticoagulation. 4 Passengers with open pulmonary TB should not travel on public transport; those with a current closed pneumothorax should not travel by air and should delay their flight until one week after resolution on CXR.4 There are currently no proven personal measures to prevent infection when travelling; population measures remain the domain of public health. For passengers who may be at risk from dehydration, advice on drinking adequate water is prudent.
What are the challenges for respiratory professionals and the travel industry? Various questions remain unanswered, particularly regarding air travel. We do not know how many patients are deterred from travel, how many suffer adverse consequences, the best pre-flight assessment method, or whether in-flight oxygen is effective. The ongoing nationwide UK Flight
Outcomes Study should provide some answers. Finally, the cost and inconvenience of flying for those with lung disease may prove prohibitive. Even when the medical issues are better defined, this hurdle may remain. Airlines, tour operators and insurers may have to review policies and procedures if patients with lung disease are to enjoy the same opportunities to fly as those without.
